Overview
Canada cannabis consumer goods firm's Q1 revenue grew 22% yr/yr
Q1 adjusted EBITDA rose 65% yr/yr, driven by improved gross profits
Company announced share repurchase program for up to 68.9 mln common shares
Outlook
Auxly plans C$10 mln to C$12 mln in capital projects at Leamington facility in 2026
Result Drivers
COST REDUCTIONS - Co attributed improved gross margin to manufacturing process improvements, higher cultivation yields, efficiency gains at Charlottetown facility, and strategic procurement initiatives
OPERATING EFFICIENCY - SG&A expenses rose in absolute terms to support higher sales, but declined as a percentage of revenue, indicating improved efficiency
Company press release: ID:nCNWrWQnFa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
C$39.80 mln
C$37.90 mln (1 Analyst)
Q1 Net Income
C$3.50 mln
Q1 Adjusted EBITDA
C$12.30 mln
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Auxly Cannabis Group Inc is C$0.25, about 78.6% above its May 13 closing price of C$0.14
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)